|Bid||62.50 x 1000|
|Ask||85.00 x 800|
|Day's Range||56.89 - 64.50|
|52 Week Range||52.60 - 84.23|
|Beta (5Y Monthly)||1.13|
|PE Ratio (TTM)||43.70|
|Earnings Date||Nov 02, 2022 - Nov 07, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||73.08|
Subscribe to Yahoo Finance Plus to view Fair Value for GMED
Globus Medical's (GMED) Musculoskeletal Solutions products generate solid revenues on growth in spine and trauma implant portfolios.
Joining today's call from Globus Medical will be Dan Scavilla, president and chief executive officer; and Keith Pfeil, senior vice president and chief financial officer. This review is being made available via webcast, accessible through the Investor Relations section of the Globus Medical website at www.globusmedical.com.
Globus Medical (GMED) delivered earnings and revenue surprises of 3.70% and 2%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?